Management of hepatocellular carcinoma recurrence after liver transplantation |
| |
Authors: | Parul D Agarwal Michael R Lucey |
| |
Institution: | Division of Gastroenterology and Hepatology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, 1685 Highland Avenue, Suite 4224, Madison, WI 53705, United States |
| |
Abstract: | Despite careful selection for liver transplantation (LT) of patients with hepatocellular carcinoma (HCC), HCC may still recur after LT and is frequently associated with dismal outcome. Tumor factors, including serum alpha-fetoprotein (AFP), the presence of microvascular invasion, tumor grade/differentiation, and largest tumor size are amongst the most important predictors of recurrence after transplantation. The nature of recurrence can be highly variable, but often presents with extra-hepatic involvement. As such, management of patients with HCC can be challenging, and consensus guidelines are lacking. Curative options, with surgery or ablation, which may be applicable in patients with isolated intra-or extrahepatic metastases, offer the best chance for improved long-term outcome in patients with HCC recurrence after transplantation. Most patients with recurrence have unresectable disease, and may benefit from palliative treatments, including intra-arterial therapies and/or systemic therapy. |
| |
Keywords: | (In addition to title) Alpha fetoprotein Ablation Trans-arterial chemoembolization Chemotherapy HCC Hepatocellular carcinoma LT Liver transplantation AFP Alpha fetoprotein TACE Trans-arterial chemoembolization mTOR Mammalian target of rapamycin |
本文献已被 ScienceDirect 等数据库收录! |
|